Skip to main content

Free Content Serious adverse reactions in a tuberculosis programme setting in Kyrgyzstan [Notes from the field]

Download Article:
 Download
(PDF 239.205078125 kb)
 
Serious adverse reactions among new smear-positive patients were studied in a programme setting in Kyrgyzstan. Two per cent of patients on tuberculosis (TB) treatment had to interrupt treatment for ≥1 week, and more than 80% of the reactions occurred during the first month of treatment. Pyrazinamide was the most common causative agent, followed by rifampicin.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Kyrgyzstan; adverse reactions; anti-tuberculosis drugs

Document Type: Short Communication

Affiliations: 1: Centre for International Health, University of Bergen, Bergen, Norway 2: Project HOPE, Bishkek, Kyrgyzstan 3: International Union Against Tuberculosis and Lung Disease, Paris, France

Publication date: 2009-12-01

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more